Cancer of the uterine cervix: Sensitivity and specificity of serum squamous cell carcinoma antigen determinations

Duk, Jitze M.; Bruijn, H.W.A. de; Groenier, Klaas H.; Hollema, Harry; Hoor, Klaske A. ten; Krans, M.; Aalders, Jan G.

doi:10.1016/0090-8258(90)90430-s

Cited by 84 publications

(72 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In case of CA 125 the median levels were not stage dependent. In contrast with the results of Duk et al [8], we did not find a correlation between tumor size and marker levels in a subpopulation of stage IB and IIA patients. Unlike SCC, the serum CA 125 level was found to be a useful indicator for progression.…”

Section: Discussioncontrasting

confidence: 57%

“…Following the recommendations of the manufacturer 2.5 ng/ml was chosen as a cutoff level for SCC leading to a specificity of 99%. When this value was used in other studies elevated serum levels were found in 4 4 -57% of patients with cervical cancer [8,9]. In our study the sensitivity of this marker for cervical cancer was only 26%, probably as a result of the relatively high number of lowstage patients (82% stage IB or IIA).…”

Section: Discussionmentioning

confidence: 39%

“…Squamous cell carcinoma antigen (SCC) is a subfraction of the tumor anti gen TA-4 and was isolated from a squamous cell carcinoma of the uterine cervix [7]. In prior studies of patients with squamous cell carcinoma of the cervix, SCC serum levels have been shown to correlate with stage of disease, to be predictive of response, and to aid in the detection of recur rence [8][9][10]. CA 125 is a tumor marker mainly used for the monitoring of treatment results in patients with ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations

Massuger¹,

Koper²,

Thomas³

et al. 1997

Gynecologic Oncology

View full text Add to dashboard Cite

Staging of cervical cancer is routinely performed by means of examination under anesthesia in combination with radiographic and/or endoscopic techniques. This "clinical" staging leads to 1 0 -25% misclassification, mostly due to positive lymph nodes or lymph or blood vessel invasion. Determination of pretreatment squamous cell carcinoma antigen (SCC) and CA 125 serum levels may so lv e part of this staging problem and may improve the selec tion o f the most appropriate individual therapy. Using 2.5 ng/ml (SCC) and 35 U/ml (CA 125) as cutoff levels, we studied 99 pa riente retrospectively. Elevated levels were found in 27% (SCC) and 23% (CA 125). In clinical stage IB or IIA disease 45/81 patients had positive nodes or lymph or blood vessel invasion at operation. Of th ese patients 49% had elevated serum levels of SCC or CA 125. Strongest correlation was found with blood vessel invasion (57%). Only 19% of low-stage patients without evidence of vascular spread o f disease had positive levels. The positive predictive value of SC C and CA 125 for detection of vascular spread of disease in low-stage cervical cancer was 76%. In most centers surgery is the primary treatment of choice in low-stage cervical cancer. Never theless, with respect to patient survival, results of primary surgery and primary radiotherapy are comparable. Radiotherapy given in an adjuvant setting leads to a high incidence of severe complica tions. In order to overcome part of these complications one should consider radiotherapy as the primary therapy of choice in patients with clinical stage IB or IIA cervical cancer with elevated pretreat ment SCC or CA 125 levels.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 39%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations

Massuger¹,

Koper²,

Thomas³

et al. 1997

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Serum SCC concentration has a sensitivity between 56% and 86% and specificity between 83% and 100% for detecting recurrent squamous cell cervical cancer (386,388,392,396,398,401,407,409,412 ). With the use of SCC, a lead time of up to 14 months for detecting recurrent disease has been reported, with a mean or median between 2 and 6 months (386, 388, 396 -398, 400, 401, 403, 405, 407 ).…”

Section: Use Of Scc In Monitoring Response To Treatment and Early Detmentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic patients with typical hypervascular lesions >2 cm in size are consistent with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, especially in the absence of measurable disease. Although several urine markers have been proposed for bladder cancer, none at present can replace routine cystoscopy and cytology in the management of patients with this malignancy. Some may, however, be used as complementary adjuncts to direct more effective use of clinical procedures. Although carcinoembryonic antigen and CA 19-9 have been proposed for use gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.

show abstract

“…The distribution of CEA, CA125 and SCC between vaginal fluid and peripheral circulation is similar to that described between serum and various other body fluids or cell content in some physiological conditions or benign and malignant diseases, concerning normal endometrium and uterine fluid (18), amniotic fluid and maternal serum (16), follicular fluid and serum (21), and either fluid from functional and organic cysts (8, 24), or benign and even malignant ovarian tumors and serum (13,25).…”

Section: Discussionmentioning

confidence: 71%

Vaginal Fluid and Serum CEA, CA125 and SCC in Normal Conditions and in Benign and Malignant Diseases of the Genital Tract

et al. 1997

View full text Add to dashboard Cite

Carcinoembryonic antigen (CEA), CAI 25, and squamous cell carcinoma antigen (SCC) were evaluated in paired vaginal fluid and serum samples from 69 women, mean age 40.6 (20-78) years. Fifteen of the subjects were normal females (controls), 12 were pregnant, 20 had benign gynecological diseases. 5 presented severe cervical dysplasias and 17 suffered from cancer of the genital tract. Highly elevated CEA, CAI25 and SCC concentrations (median, range) were found in vaginal fluid: 186 ng/nil (12-5420); 890 U/ml (54-65000); 1600 ng/ml (27-13000) respectively, compared with those in the paired serum samples: I nglml (0.5S8.6): 12 U/ml (3.0-1 590): I ngiml (0.3-19). Vaginal fluid CEA. CAI25 and SCC values were significantly different among the five studied groups ( p <0.0002; p (0.02: p < 0.002 respectively). being significantly higher in the patients with benign gynecological diseases, compared with those in the patients with malignancies of the genital tract (p < 0,0001; p < 0.02; p < 0.005), and those in controls ( p < 0.02; p < 0.007: p < 0.02 respectively).The results of this study suggest that: 1) CEA. CAI25 and SCC seem to be normal constituents of vaginal fluid. 2) The distribution of CEA, CAI25 and SCC between vaginal fluid and the circulation is affected by pregnancy, inflammation and cancer of the genital tract.

show abstract

Cancer of the uterine cervix: Sensitivity and specificity of serum squamous cell carcinoma antigen determinations

Cited by 84 publications

References 20 publications

Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations

Improvement of Clinical Staging in Cervical Cancer with Serum Squamous Cell Carcinoma Antigen and CA 125 Determinations

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Vaginal Fluid and Serum CEA, CA125 and SCC in Normal Conditions and in Benign and Malignant Diseases of the Genital Tract

Contact Info

Product

Resources

About